Tuesday, November 18, 2025 12:23:51 PM
Landed like a wet turd.
Only item of note is the issuance of another 210MM shares of common, bringing to total dilution after the ABBIE announcement to 1.1BB shares; roughly 40% of their 2.7BB total outstanding.
Market cap is over 3MM right now on a company that has yet to record over 1MM in revs, has yet to deliver anything tangible from the ABBIE investment, and is currently operating at a deficit...additional share issuances are likely. Between the common dilution the 2025 issuance of additional (convertible) Pref shares, it's highly unlikely that we will ever see this ticker rise in a meaningful way.
Only item of note is the issuance of another 210MM shares of common, bringing to total dilution after the ABBIE announcement to 1.1BB shares; roughly 40% of their 2.7BB total outstanding.
Market cap is over 3MM right now on a company that has yet to record over 1MM in revs, has yet to deliver anything tangible from the ABBIE investment, and is currently operating at a deficit...additional share issuances are likely. Between the common dilution the 2025 issuance of additional (convertible) Pref shares, it's highly unlikely that we will ever see this ticker rise in a meaningful way.
Recent SHMN News
- SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery • ACCESS Newswire • 11/06/2025 02:30:00 PM
- SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development • ACCESS Newswire • 11/04/2025 02:30:00 PM
